

Edgar Filing: Symmetry Medical Inc. - Form 10-Q

Symmetry Medical Inc.  
Form 10-Q  
November 08, 2011

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION  
Washington, D.C. 20549

FORM 10-Q

QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d)  
OF THE SECURITIES EXCHANGE ACT OF 1934

For the quarterly period ended October 1, 2011

Commission File Number: 001-32374

SYMMETRY MEDICAL INC.  
(Exact name of registrant as specified in its charter)

Delaware  
(State or other jurisdiction of incorporation or organization)

35-1996126  
(I.R.S. Employer Identification No.)

3724 North State Road 15, Warsaw, Indiana  
(Address of principal executive offices)

46582  
(Zip Code)

(574) 268-2252  
(Registrant's telephone number, including area code)

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.  Yes  No

Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (S232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files).

Yes  No

Indicate by checkmark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company. See the definitions of "large accelerated filer," "accelerated filer" and "smaller reporting company" in Rule 12b-2 of the Exchange Act.

Large accelerated filer   
Non-accelerated filer  (Do not check if a smaller reporting company)

Accelerated filer   
Smaller reporting company

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).   
Yes  No

Edgar Filing: Symmetry Medical Inc. - Form 10-Q

The number of shares outstanding of the registrant's common stock as of November 8, 2011 was 36,316,066 shares.

---

TABLE OF CONTENTS

|                                     |  |    |
|-------------------------------------|--|----|
| <b>PART I FINANCIAL INFORMATION</b> |  |    |
| Item 1                              | Financial Statements:  |    |
|                                     | Condensed Consolidated Balance Sheets: As of October 1, 2011 and January 1, 2011                                 | 4  |
|                                     | Condensed Consolidated Statements of Operations: Three and Nine Months Ended October 1, 2011 and October 2, 2010 | 5  |
|                                     | Condensed Consolidated Statements of Cash Flows: Nine Months Ended October 1, 2011 and October 2, 2010           | 6  |
|                                     | Notes to Condensed Consolidated Financial Statements   | 7  |
| Item 2                              | Management's Discussion and Analysis of Financial Condition and Results of Operations                            | 12 |
| Item 3                              | Quantitative and Qualitative Disclosures about Market Risk   | 15 |
| Item 4                              | Controls and Procedures  | 15 |
| <b>PART II OTHER INFORMATION</b>    |  |    |
| Item 1                              | Legal Proceedings  | 16 |
| Item 1A                             | Risk Factors   | 16 |
| Item 5                              | Other Information  |    |
| Item 6                              | Exhibits   | 16 |
|                                     | Signatures   | 17 |

### Cautionary Note Regarding Forward-Looking Statements

Throughout this Quarterly Report on Form 10-Q or in other reports or registration statements filed from time to time with the Securities and Exchange Commission (SEC) under the Securities Exchange Act of 1934, or under the Securities Act of 1933, as well as in documents we incorporate by reference or in press releases or oral statements made by our officers or representative, we may make statements that express our opinions, expectations or projections regarding future events or future results, in contrast with statements that reflect historical facts. These predictive statements, which we generally precede or accompany by such typical conditional words such as “anticipate,” “intend,” “believe,” “estimate,” “plan,” “seek,” “project,” “potential,” or “expect,” or by the words “may,” “will,” “could,” or “should,” expressions or terminology are intended to operate as “forward-looking statements” of the kind permitted by the Private Securities Litigation Reform Act of 1995. That legislation protects such predictive statements by creating a “safe harbor” from liability in the event that a particular prediction does not turn out as anticipated.

Forward-looking statements convey our current expectations or forecast future events. While we always intend to express our best judgment when we make statements about what we believe will occur in the future, and although we base these statements on assumptions that we believe to be reasonable when made, these forward-looking statements are not a guarantee of performance, and you should not place undue reliance on such statements. Forward-looking statements are subject to many uncertainties and other variable circumstances, many of which are outside of our control, that could cause our actual results and experience to differ materially from those we thought would occur.

We also refer you to and believe that you should carefully read the “Cautionary Note Regarding Forward-Looking Statements” and “Risk Factors” portions of our Annual Report for fiscal 2010 on Form 10-K, as well as in other reports which we file with the Securities and Exchange Commission, to better understand the risks and uncertainties that are inherent in our business and in owning our securities. These reports are available publicly on the SEC website, [www.sec.gov](http://www.sec.gov), and on our website, [www.symmetrymedical.com](http://www.symmetrymedical.com).

Any forward-looking statements which we make in this report or in any of the documents that are incorporated by reference herein speak only as of the date of such statement, and we undertake no ongoing obligation to update such statements. Comparisons of results between current and any prior periods are not intended to express any future trends or indications of future performance, unless expressed as such, and should only be viewed as historical data.

PART I FINANCIAL INFORMATION  
ITEM I. FINANCIAL STATEMENTS

## SYMMETRY MEDICAL INC.

CONDENSED CONSOLIDATED BALANCE SHEETS  
(In Thousands)

|  | October 1,<br>2011<br>(unaudited) | January 1,<br>2011 |
|--|-----------------------------------|--------------------|
| <b>ASSETS:</b>                                     |                                   |                    |
| Current Assets:                                    |                                   |                    |
| Cash and cash equivalents                          | \$20,559                          | \$15,067           |
| Accounts receivable, net                           | 48,313                            | 50,457             |
| Inventories  | 80,633                            | 70,373             |
| Refundable income taxes                            | 4,804                             | 1,911              |
| Deferred income taxes                              | 5,506                             | 4,597              |
| Other current assets                               | 3,514                             | 3,281              |
| <b>Total current assets</b>                        | <b>163,329</b>                    | <b>145,686</b>     |
| Property and equipment, net                        | 105,140                           | 107,879            |
| Goodwill   | 157,530                           | 154,218            |
| Intangible assets, net of accumulated amortization | 42,324                            | 39,601             |
| Other assets                                       | 3,607                             | 2,570              |
| <b>Total Assets</b>                                | <b>\$471,930</b>                  | <b>\$449,954</b>   |
| <b>LIABILITIES AND SHAREHOLDERS' EQUITY:</b>       |                                   |                    |
| Current Liabilities:                               |                                   |                    |
| Accounts payable                                   | \$22,724                          | \$23,097           |
| Accrued wages and benefits                         | 8,954                             | 6,808              |
| Other accrued expenses                             | 5,516                             | 3,881              |
| Accrued income taxes                               | 875                               | 233                |
| Deferred income taxes                              | 41                                | -                  |
| Revolving line of credit                           | 5,853                             | 3,692              |
| Current portion of capital lease obligations       | 490                               | 454                |
| Current portion of long-term debt                  | 701                               | 1,397              |
| <b>Total current liabilities</b>                   | <b>45,154</b>                     | <b>39,562</b>      |
| Accrued income taxes                               | 6,664                             | 6,564              |
| Deferred income taxes                              | 18,167                            | 17,692             |
| Capital lease obligations, less current portion    | 2,046                             | 2,418              |
| Long-term debt, less current portion               | 94,500                            | 87,349             |
| <b>Total Liabilities</b>                           | <b>166,531</b>                    | <b>153,585</b>     |
| Shareholders' Equity:                              |                                   |                    |
|  | 4                                 | 4                  |

Edgar Filing: Symmetry Medical Inc. - Form 10-Q

Common Stock, \$.0001 par value; 75,000 shares authorized; shares issued October 1, 2011--36,284; January 1, 2011--35,950

|   |                  |                  |
|---|------------------|------------------|
| Additional paid-in capital                        | 281,860          | 279,592          |
| Retained earnings                                 | 20,312           | 14,248           |
| Accumulated other comprehensive income            | 3,223            | 2,525            |
| <b>Total Shareholders' Equity</b>                 | <b>305,399</b>   | <b>296,369</b>   |
| <b>Total Liabilities and Shareholders' Equity</b> | <b>\$471,930</b> | <b>\$449,954</b> |

See accompanying notes to condensed consolidated financial statements.

## SYMMETRY MEDICAL INC.

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS  
(In Thousands, Except per Share Data; Unaudited)

|  | Three Months Ended |                    | Nine Months Ended  |                    |
|--|--------------------|--------------------|--------------------|--------------------|
|  | October 1,<br>2011 | October 2,<br>2010 | October 1,<br>2011 | October 2,<br>2010 |
| Revenue  | \$84,039           | \$91,538           | \$274,538          | \$264,856          |
| Cost of revenue  | 68,285             | 71,708             | 217,233            | 207,627            |
| Gross profit   | 15,754             | 19,830             | 57,305             | 57,229             |
| Selling, general and administrative expenses                         | 13,839             | 12,248             | 42,469             | 37,124             |
| Facility closure and severance costs                                 | 253                | 57                 | 2,526              | 917                |
| Operating Income   | 1,662              | 7,525              | 12,310             | 19,188             |
| Other (income) expense:  |                    |                    |                    |                    |
| Interest expense   | 964                | 1,504              | 2,754              | 4,565              |
| Derivatives valuation gain   | -                  | (389 )             | -                  | (1,177 )           |
| Other  | (160 )             | 715                | 591                | 796                |
| Income before income taxes   | 858                | 5,695              | 8,965              | 15,004             |
| Income tax expense   | 331                | 2,123              | 2,901              | 5,322              |
| Net income   | \$527              | \$3,572            | \$6,064            | \$9,682            |
| Net income per share:  |                    |                    |                    |                    |
| Basic  | \$0.01             | \$0.10             | \$0.17             | \$0.27             |
| Diluted  | \$0.01             | \$0.10             | \$0.17             | \$0.27             |
| Weighted average common shares and equivalent shares<br>outstanding: |                    |                    |                    |                    |
| Basic  | 35,546             | 35,456             | 35,537             | 35,449             |
| Diluted  | 36,021             | 35,870             | 36,000             | 35,802             |

See accompanying notes to condensed consolidated financial statements.

## SYMMETRY MEDICAL INC.

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOW  
(In Thousands; Unaudited)

|   | Nine Months Ended  |                    |
|---|--------------------|--------------------|
|   | October 1,<br>2011 | October 2,<br>2010 |
| <b>Operating activities</b>   |                    |                    |
| Net income  | \$6,064            | \$9,682            |
| Adjustments to reconcile net income to net cash provided by operating activities: |                    |                    |
| Depreciation  | 13,811             | 13,576             |
| Amortization  | 2,138              | 2,198              |
| Net loss on sale of assets  | 77                 | 103                |
| Deferred income tax provision   | (283 )             | 666                |
| Stock-based compensation  | 2,174              | 693                |
| Derivative valuation gain   | -                  | (1,177 )           |
| Foreign currency transaction (gain) loss  | (1,474 )           | 566                |
| Change in operating assets and liabilities:                                       |                    |                    |
| Accounts receivable   | 2,873              | (10,288 )          |
| Other assets  | (1,246 )           | (506 )             |
| Inventories   | (8,093 )           | (10,394 )          |
| Current income taxes  | (2,215 )           | 112                |
| Accounts payable  | (942 )             | 9,093              |
| Accrued expenses and other  | 5,314              | (2,400 )           |
| <b>Net cash provided by operating activities</b>                                  | <b>18,198</b>      | <b>11,924</b>      |
| <b>Investing activities</b>   |                    |                    |
| Purchases of property and equipment   | (10,426 )          | (9,592 )           |
| Proceeds from the sale of property and equipment                                  | 113                | 611                |
| Acquisition, net of cash received   | (11,000 )          | -                  |
| <b>Net cash used in investing activities</b>                                      | <b>(21,313 )</b>   | <b>(8,981 )</b>    |
| <b>Financing activities</b>   |                    |                    |
| Proceeds from revolving credit agreement borrowings                               | 52,819             | 40,894             |
| Payments on revolving credit agreement borrowings                                 | (45,319 )          | (29,231 )          |
| Proceeds from (payments on) short term borrowings, net                            | 2,441              | (1,081 )           |
| Issuance of bank term loan  | -                  | 2,711              |
| Payments on bank term loans and capital lease obligations                         | (1,432 )           | (16,383 )          |
| Proceeds from the issuance of common stock  | 79                 | 99                 |
| <b>Net cash provided by (used in) financing activities</b>                        | <b>8,588</b>       | <b>(2,991 )</b>    |
| Effect of exchange rate changes on cash   | 19                 | (302 )             |
| <b>Net increase (decrease) in cash and cash equivalents</b>                       | <b>5,492</b>       | <b>(350 )</b>      |



Edgar Filing: Symmetry Medical Inc. - Form 10-Q

|  |          |          |
|--|----------|----------|
| Cash and cash equivalents at beginning of period | 15,067   | 14,219   |
| Cash and cash equivalents at end of period       | \$20,559 | \$13,869 |
| Supplemental disclosures:                        |          |          |
| Cash paid for interest                           | \$2,441  | \$4,018  |
| Cash paid for income taxes                       | \$5,316  | \$3,728  |

See accompanying notes to condensed consolidated financial statements.

SYMMETRY MEDICAL INC.  
 NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS  
 (In Thousands, Except Per Share Data; Unaudited)

### 1. Basis of Presentation

The condensed consolidated financial statements include the accounts of Symmetry Medical Inc. and its wholly-owned subsidiaries (collectively referred to as the Corporation). The Corporation is a global supplier of integrated products consisting primarily of surgical implants, instruments and cases to orthopedic and other medical device companies.

The condensed consolidated financial statements of the Corporation have been prepared without audit, pursuant to the rules and regulations of the Securities and Exchange Commission. Certain information and footnote disclosures normally included in financial statements prepared in accordance with generally accepted accounting principles have been condensed or omitted pursuant to such rules and regulations. In the opinion of management, the accompanying condensed consolidated financial statements contain all adjustments of a normal recurring nature considered necessary to present fairly the consolidated financial position of the Corporation, its results of operations and cash flows. The Corporation's results are subject to seasonal fluctuations. Interim results are not necessarily indicative of results for a full year. The condensed consolidated financial statements included herein should be read in conjunction with the fiscal year 2010 consolidated financial statements and the notes thereto included in the Corporation's Annual Report on Form 10-K for fiscal year 2010.

The Corporation's fiscal year is the 52 or 53 week period ending on the Saturday closest to December 31. Fiscal year 2011 is a 52 week year ending December 31, 2011. The Corporation's interim quarters for 2011 are 13 weeks long and quarter-end dates have been set as April 2, 2011, July 2, 2011 and October 1, 2011. Fiscal year 2010 was a 52 week year (ending January 1, 2011). The Corporation's interim quarters for 2010 were 13 weeks long, ending April 3, 2010, July 3, 2010 and October 2, 2010. References in these condensed consolidated financial statements to the three months ended refer to these financial periods, respectively. The Corporation has evaluated subsequent events for the quarter ended October 1, 2011, up through the date the financial statements were issued which corresponds to the time of filing with the SEC.

On August 15, 2011, the Corporation acquired the assets of PSC's Olsen Medical division for \$11,000 in cash, subject to certain post-closing adjustments. Olsen Medical manufactures a full line of single-use and reusable bipolar and monopolar forceps, cords, electrosurgical pens/pencils, electrodes, and accessories. Olsen Medical's products are primarily sold in the United States and internationally through distributors. Refer to Note 11 for further discussion of this acquisition.

### 2. Inventories

Inventories consist of the following:

|                           | October 1,<br>2011<br>(unaudited) | January 1,<br>2011 |
|---------------------------|-----------------------------------|--------------------|
| Raw material and supplies | \$ 18,918                         | \$ 14,407          |
| Work-in-process           | 32,883                            | 31,739             |
| Finished goods            | 28,832                            | 24,227             |

|  |           |           |
|--|-----------|-----------|
|  | \$ 80,633 | \$ 70,373 |
|--|-----------|-----------|

### 3. Property and Equipment

Property and equipment, including depreciable lives, consists of the following:

|   | October 1,<br>2011<br>(unaudited) | January 1,<br>2011 |
|---|-----------------------------------|--------------------|
| Land  | \$ 6,423                          | \$ 6,412           |
| Buildings and improvements (20 to 40 years) | 42,073                            | 41,152             |
| Machinery and equipment (5 to 15 years)     | 148,777                           | 144,626            |
| Office equipment (3 to 5 years)             | 16,642                            | 13,959             |
| Construction-in-progress                    | 6,765                             | 7,276              |
|   | 220,681                           | 213,425            |
| Less accumulated depreciation               | (115,541 )                        | (105,546 )         |
|   | \$ 105,140                        | \$ 107,879         |

## 4. Intangible Assets

Intangible assets were acquired in connection with our business combinations over the past several years. The increase in intangible assets from January 1, 2011 is due to the Corporation's acquisition of Olsen Medical in August 2011. As of October 1, 2011, the balances of intangible assets, other than goodwill, were as follows:

|  | Weighted-Average<br>Amortization<br>Period<br>(unaudited) | Gross<br>Intangible<br>Assets<br>(unaudited) | Accumulated<br>Amortization<br>(unaudited) | Net<br>Intangible<br>Assets<br>(unaudited) |
|--|---|--|--|--|
| Acquired technology and patents                            | 10 years  | \$ 2,326                                     | \$ (1,407 )                                | \$ 919                                     |
| Acquired customers   | 18 years  | 45,552                                       | (13,591 )                                  | 31,961                                     |
| Non-compete agreements                                     | 5 years   | 405  | (349 )                                     | 56   |
| Intangible assets subject to<br>amortization               | 18 years  | 48,283                                       | (15,347 )                                  | 32,936                                     |
| Proprietary processes                                      | Indefinite  |  |  | 3,530                                      |
| In process research and<br>development                     | Indefinite  |  |  | 610  |
| Trademarks   | Indefinite  |  |  | 5,248                                      |
| Indefinite-lived intangible assets,<br>other than goodwill |   |  |  | 9,388                                      |
| <b>Total</b>   |   |  |  | <b>\$ 42,324</b>                           |

As of January 1, 2011, the balances of intangible assets, other than goodwill, were as follows:

|  | Weighted-Average<br>Amortization<br>Period | Gross<br>Intangible<br>Assets | Accumulated<br>Amortization | Net<br>Intangible<br>Assets |
|--|--|-------------------------------|-----------------------------|-----------------------------|
| Acquired technology and patents                            | 10 years                                   | \$ 2,324                      | \$ (1,284 )                 | \$ 1,040                    |
| Acquired customers   | 18 years                                   | 42,503                        | (11,669 )                   | 30,834                      |
| Non-compete agreements                                     | 5 years                                    | 590                           | (442 )                      | 148                         |
| Intangible assets subject to<br>amortization               | 17 years                                   | 45,417                        | (13,395 )                   | 32,022                      |
| Proprietary processes                                      | Indefinite                                 |                               |                             | 3,525                       |
| Trademarks   | Indefinite                                 |                               |                             | 4,054                       |
| Indefinite-lived intangible assets,<br>other than goodwill |  |                               |                             | 7,579                       |
| <b>Total</b>   |  |                               |                             | <b>\$ 39,601</b>            |

## 5. New Accounting Pronouncements

Presentation of Comprehensive Income: In June 2011, the Financial Accounting Standards Board ("FASB") issued Accounting Standards Update ("ASU") No. 2011-05, "Comprehensive Income (ASC Topic 220): Presentation of Comprehensive Income," ("ASU 2011-05") which amends current comprehensive income guidance. This accounting update eliminates the option to present the components of other comprehensive income as part of the statement of

shareholders' equity. Instead, the Company must report comprehensive income in either a single continuous statement of comprehensive income which contains two sections, net income and other comprehensive income, or in two separate but consecutive statements. This standard will be effective for public companies during the interim and annual periods beginning after December 15, 2011 with early adoption permitted. The adoption of ASU 2011-05 will not have an impact on the Corporation's consolidated financial position, results of operations or cash flows as it only requires a change in the format of the current presentation.

## 6. Segment Reporting

The Corporation primarily designs, develops and manufactures implants and related surgical instruments and cases for orthopedic device companies and companies in other medical device markets such as arthroscopy, dental, laparoscopy, osteobiologic and endoscopy. The Corporation also sells products to the aerospace industry. The Corporation manages its business in multiple operating segments. Because of the similar economic characteristics of these operations, including the nature of the products, comparable level of FDA regulations, and same or similar customers, those operations have been aggregated for segment reporting purposes. The results of one segment which sells exclusively to aerospace customers has not been disclosed separately as it does not meet the quantitative disclosure requirements.

The Corporation is a multi-national Corporation with operations in the United States, United Kingdom, France, Ireland and Malaysia. As a result, the Corporation's financial results can be impacted by currency exchange rates in the foreign markets in which the Corporation sells its products. Revenues are attributed to geographic locations based on the location to which we ship our products.

## 6. Segment Reporting (Continued)

## Revenue to External Customers:

|                         | Three Months Ended                |                                   | Nine Months Ended                 |                                   |
|-------------------------|-----------------------------------|-----------------------------------|-----------------------------------|-----------------------------------|
|                         | October 1,<br>2011<br>(unaudited) | October 2,<br>2010<br>(unaudited) | October 1,<br>2011<br>(unaudited) | October 2,<br>2010<br>(unaudited) |
| United States           | \$ 60,541                         | \$ 67,508                         | \$ 198,293                        | \$ 194,436                        |
| Ireland                 | 5,507                             | 8,544                             | 18,117                            | 25,058                            |
| United Kingdom          | 6,590                             | 6,906                             | 22,149                            | 20,649                            |
| Other foreign countries | 11,401                            | 8,580                             | 35,979                            | 24,713                            |
| Total net revenues      | \$ 84,039                         | \$ 91,538                         | \$ 274,538                        | \$ 264,856                        |

## Concentration of Credit Risk:

A substantial portion of the Corporation's revenue is derived from a limited number of customers. Revenue from customers of the Corporation which individually account for 10% or more of the Corporation's revenue is as follows:

Three months ended October 1, 2011 – Two customers represented approximately 28.5% and 12.7% of revenue, respectively.

Nine months ended October 1, 2011 – Two customers represented approximately 31.5% and 11.1% of revenue, respectively.

Three months ended October 2, 2010 – Two customers represented approximately 30.7% and 12.4% of revenue, respectively.

Nine months ended October 2, 2010 – Two customers represented approximately 31.9% and 10.6% of revenue, respectively.

## Revenue by Product Category:

Following is a summary of the composition by product category of the Corporation's revenue to external customers. Revenues from aerospace products are included in the "other" category.

|                    | Three Months Ended                |                                   | Nine Months Ended                 |                                   |
|--------------------|-----------------------------------|-----------------------------------|-----------------------------------|-----------------------------------|
|                    | October 1,<br>2011<br>(unaudited) | October 2,<br>2010<br>(unaudited) | October 1,<br>2011<br>(unaudited) | October 2,<br>2010<br>(unaudited) |
| Instruments        | \$ 33,583                         | \$ 36,027                         | \$ 110,593                        | \$ 103,096                        |
| Implants           | 26,735                            | 28,332                            | 80,436                            | 85,058                            |
| Cases              | 17,573                            | 21,495                            | 65,565                            | 60,127                            |
| Other              | 6,148                             | 5,684                             | 17,944                            | 16,575                            |
| Total net revenues | \$ 84,039                         | \$ 91,538                         | \$ 274,538                        | \$ 264,856                        |



## 7. Net Income Per Share

The following table sets forth the computation of earnings per share.

|   | Three Months Ended                |                                   | Nine Months Ended                 |                                   |
|---|-----------------------------------|-----------------------------------|-----------------------------------|-----------------------------------|
|   | October 1,<br>2011<br>(unaudited) | October 2,<br>2010<br>(unaudited) | October 1,<br>2011<br>(unaudited) | October 2,<br>2010<br>(unaudited) |
| <b>Earnings per share - Basic:</b>                          |                                   |                                   |                                   |                                   |
| Net income  | \$ 527                            | \$ 3,572                          | \$ 6,064                          | \$ 9,682                          |
| Less: Undistributed earnings allocated to nonvested stock   | (4 )                              | (33 )                             | (46 )                             | (89 )                             |
| Income available to common shares - Basic                   | 523                               | 3,539                             | 6,018                             | 9,593                             |
| <b>Weighted-average common shares outstanding - Basic</b>   |                                   |                                   |                                   |                                   |
|   | 35,546                            | 35,456                            | 35,537                            | 35,449                            |
| <b>Earnings per share - Basic</b>                           | <b>\$ 0.01</b>                    | <b>\$ 0.10</b>                    | <b>\$ 0.17</b>                    | <b>\$ 0.27</b>                    |
| <b>Earnings per share - Diluted:</b>                        |                                   |                                   |                                   |                                   |
| Net income  | \$ 527                            | \$ 3,572                          | \$ 6,064                          | \$ 9,682                          |
| Less: Undistributed earnings allocated to nonvested stock   | -                                 | -                                 | -                                 | -                                 |
| Income available to common shares - Diluted                 | 527                               | 3,572                             | 6,064                             | 9,682                             |
| <b>Weighted-average common shares outstanding - Basic</b>   |                                   |                                   |                                   |                                   |
|   | 35,546                            | 35,456                            | 35,537                            | 35,449                            |
| Effect of dilution  | 475                               | 414                               | 463                               | 353                               |
| <b>Weighted-average common shares outstanding - Diluted</b> | <b>36,021</b>                     | <b>35,870</b>                     | <b>36,000</b>                     | <b>35,802</b>                     |
| <b>Earnings per share - Diluted</b>                         | <b>\$ 0.01</b>                    | <b>\$ 0.10</b>                    | <b>\$ 0.17</b>                    | <b>\$ 0.27</b>                    |

The diluted weighted-average share calculations for the three and nine months ended October 1, 2011 and October 2, 2010 do not include performance based restricted stock awarded in 2011 totaling 256 shares and in 2010 totaling 66 shares, respectively, due to the respective measurement period not being complete.

## 8. Commitments and Contingencies

**Legal & Environmental Matters.** The Corporation is involved, from time to time, in various contractual, product liability, patent (or intellectual property) and other claims and disputes incidental to its business. Currently, there is no environmental or other litigation pending or, to the knowledge of the Corporation, threatened, that the Corporation expects to have a material adverse effect on its financial condition, results of operations or liquidity. While litigation is subject to uncertainties and the outcome of litigated matters is not predictable with assurance, the Corporation currently believes that the disposition of all pending or, to the knowledge of the Corporation, threatened claims and disputes, individually or in the aggregate, should not have a material adverse effect on the Corporation's consolidated financial condition, results of operations or liquidity.



Following the discovery of certain accounting irregularities at our Sheffield, UK operating unit (as further described in this Form 10-Q at Part II, Item 1), the Audit Committee self-reported the matter to the staff of the Securities and Exchange Commission (SEC) in October 2007. Thereafter, the SEC commenced an informal inquiry into this matter. The Corporation has fully cooperated with the SEC in its investigation. At this time, the Corporation is unable to predict the timing of the ultimate resolution of this investigation or the impact thereof.

**Unconditional Purchase Obligations.** The Corporation has contracts to purchase minimum quantities of cobalt chrome, titanium and nickel alloys through July 2014. Based on contractual pricing at October 1, 2011, remaining minimum purchase obligations total \$26,719. Purchases under cobalt chrome, titanium and nickel alloys contracts total approximately \$8,980 for the nine month period ended October 1, 2011. These purchases are not in excess of our forecasted requirements. Additionally, as of October 1, 2011, the Corporation has \$1,923 of commitments to complete capital projects in progress.

## 9. Comprehensive Income (Loss)

Comprehensive income (loss) is comprised of net income, gains (losses) resulting from currency translations of foreign entities and unrealized gains (losses) on our derivative designated as a hedge. Comprehensive income (loss) consists of the following:

|  | Three Months Ended |                    | Nine Months Ended  |                    |
|--|--------------------|--------------------|--------------------|--------------------|
|  | October 1,<br>2011 | October 2,<br>2010 | October 1,<br>2011 | October 2,<br>2010 |
|  | (unaudited)        |                    | (unaudited)        |                    |
| Net Income                               | \$ 527             | \$ 3,572           | \$ 6,064           | \$ 9,682           |
| Foreign currency translation adjustments | (4,378 )           | 4,981              | 698                | (1,032 )           |
| Derivative, net of tax benefit (1)       | -                  | 14                 | -                  | (50 )              |
| Comprehensive income (loss)              | \$ (3,851 )        | \$ 8,567           | \$ 6,762           | \$ 8,600           |

(1) Unrealized gains (losses) are net of tax (expenses) benefits of \$(9) for the three month period ended October 2, 2010 and \$35 for the nine month period ended October 2, 2010.

## 10. Facility Closure and Severance Costs

Results of Operations include pre-tax charges of \$253 and \$57 for the three months ended October 1, 2011 and October 2, 2010, respectively, and \$2,526 and \$917 for the nine months then ended, associated with employee cost reduction and efficiency actions including the closure of our Auburn, ME facility and employee severance. For the three month period ended October 1, 2011, these costs are comprised of \$253 of severance costs compared to \$38 of severance costs, plus \$19 of moving expenses for the period ended October 2, 2010. For the nine month period ended October 1, 2011, these costs are comprised of \$2,526 of severance costs compared to \$628 of severance costs and an additional \$289 of moving expenses for the period ended October 2, 2010. As of October 1, 2011 and January 1, 2011, severance accruals related to these cost reduction and efficiency actions totaled \$962 and nil, respectively, and are included in other accrued expenses in the consolidated balance sheets. The increase in the accrual since January 1, 2011 represents severance charges incurred but not paid during the first three quarters of 2011. These costs are expected to be paid through June 2012.

## 11. Acquisition

On August 15, 2011, the Corporation acquired substantially all of the assets of PSC's Olsen Medical division (Olsen Medical) for \$11,000 in cash. Olsen Medical manufactures a full line of single-use and reusable bipolar and monopolar forceps, cords, electrosurgical pens/pencils, electrodes, and accessories. Olsen Medical's products are primarily sold in the United States and internationally through distributors. As of October 1, 2011, the preliminary allocation of the purchase price was to working capital of \$2,245, equipment of \$1,003 and intangible assets and goodwill of \$7,752. The purchase was accounted for as a business combination and the results of Olsen Medical have been included in the Corporation's Statements of Operations since the date of the acquisition. For the three and nine months ended October 1, 2011, Olsen Medical's revenue included in the Corporation's Statements of Operations was \$722 and income before income taxes was nominal. The pro forma impact of the acquisition on the Corporation's prior period Statements of Operations was not material.



## ITEM 2. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

(In millions)

### Business Overview

Symmetry Medical Inc. is a leading global source of innovative medical device solutions, including surgical instruments, orthopedic implants, and sterilization cases and trays. The Corporation's more than 2,700 teammates provide design, development and worldwide production capabilities for these products to customers in the orthopedic industry, other medical device markets, and specialized non-healthcare markets. Symmetry's trusted reputation and brands, intellectual property portfolio and commitment to innovation enable it to collaborate with hundreds of global medical device manufacturers as well as thousands of hospitals to provide solutions for today's needs and tomorrow's growth.

We offer our original equipment manufacturer (OEM) customers implants, instruments and sterilization cases and trays. Our growing hospital direct medical device distribution business is complementary to core competencies, not competitive with our OEM customers, and our salespeople call on surgeons, operating room personnel, material management and central sterile departments. We offer best-in-class quality and regulatory systems as well as customer innovation through Total Solutions® collaborations.

During the third quarter 2011, our revenue decreased \$7.5 million, or 8.2%, compared to the third quarter 2010. This decrease was primarily driven by decreased customer demand in the cases, instruments and implants product lines, partially offset by favorable foreign currency exchange rate impacts of \$1.3 million for all products. During the third quarter 2011, our combined five largest OEM customers decreased revenue by 19.9% compared to the third quarter 2010, primarily driven by a reduction in their capital expenditures and lower procedural volume. Our overall revenue in the third quarter 2011 decreased by \$10.7 million from the second quarter 2011.

In August 2011, we acquired the assets of Olsen Medical located in Louisville, Kentucky for \$11 million in cash. Olsen Medical manufactures a full line of single-use and reusable bipolar and monopolar forceps, cords, electrosurgical pens/pencils, electrodes, and accessories. Olsen Medical's products are primarily sold in the United States and internationally through distributors. We believe this acquisition enhances the product offering for Symmetry's hospital direct medical device business model. Olsen Medical reported 2010 revenue of approximately \$7.6 million. Certain key members of Olsen Medical's pre-acquisition management team continue to lead this business unit. We believe this acquisition helps continue diversification outside of the orthopedic industry and allows us to capitalize on our growing hospital direct medical device business model.

The current economy, continued higher than historical unemployment rates and lower than historical levels of surgical implant procedure growth adversely impact customer demand. We continue to be optimistic about the long-term future as the larger OEMs are increasingly focused on rationalizing their supplier base and plan to launch new products with large programs over the next three years. This will result in fewer suppliers who in turn will be expected to provide a wider range of services coupled with high quality and reduced overall costs. We believe that we are well positioned to benefit from increased OEM outsourcing and the consolidation of suppliers. We also continue to expand coverage and strengthen our product portfolio to serve our hospital direct customers.

Our strategic plan is focused on four distinct but synergistic areas:

- Trusted, industry leading orthopedic OEM supplier positioned to gain share in long-term growth segment
- Strategic, growing hospital direct medical device distribution business

- Diversification and growth opportunities through internal development or acquisitions in appropriate Medical Device OEM adjacencies and add to our direct to hospital medical device portfolio
- Robust intellectual property portfolio and dedicated R&D team to create economic and clinical value for our customers with IP protected innovations to drive future growth

Using this strategy, we strive to provide the best possible customer experience by offering superior value; the highest-quality new technology; customized services; superior support; and the integration of our products and services into our Total Solutions® offering. Historically, our growth has been driven organically from our core businesses as well as acquisitions designed to augment select areas of our business with more products, services, and technology.

### Third Quarter Results of Operations

Revenue. Revenue for the three month period ended October 1, 2011 decreased \$7.5 million, or 8.2%, to \$84.0 million from \$91.5 million for the comparable 2010 period. Revenue for each of our principal product categories in these periods was as follows:

| Product Category | Three Months Ended |                    |
|------------------|--------------------|--------------------|
|                  | October 1,<br>2011 | October 2,<br>2010 |
|                  | (unaudited)        |                    |
| Instruments      | \$ 33.6            | \$ 36.0            |
| Implants         | 26.7               | 28.3               |
| Cases            | 17.6               | 21.5               |
| Other            | 6.1                | 5.7                |
| Total            | \$ 84.0            | \$ 91.5            |

The \$7.5 million, or 8.2%, decrease in revenue resulted from decreased demand within our instruments, implants, and cases product lines. These reductions were partially offset by favorable foreign currency exchange rate fluctuations of \$1.3 million and increased demand in our other product line. Overall, we experienced lower revenues of 19.9% from our five largest OEM customers offset by increased demand from our other customers as we continue to increase our diversification. Instrument revenue decreased \$2.4 million. This decrease was driven by lower revenue from our five largest OEM customers of 17.1% related to lower demand and timing of customer launches. This organic demand decrease was partially offset by increased revenues in our hospital direct distribution business of \$1.0 million and the impact of our recent Olsen Medical acquisition, which contributed \$0.7 million in third quarter revenue. Implant revenue decreased \$1.6 million, driven by decreased revenue from our five largest OEM customers of \$2.9 million as they experience softer demand driven by lower than normal procedure growth rates. These decreases were partially offset by favorable foreign currency exchange rate fluctuations of \$0.5 million. The \$3.9 million decrease in case revenue was driven by a \$5.0 million decrease in revenue from our five largest OEM customers as a result of lower demand and timing of customer launches, partially offset by favorable foreign currency exchange rate fluctuations of \$0.5 million. Other product revenue increased \$0.5 million primarily driven by favorable foreign currency exchange rate fluctuations of \$0.2 million.

**Gross Profit.** Gross profit for the three month period ended October 1, 2011 decreased \$4.0 million, or 20.6%, to \$15.8 million from \$19.8 million for the comparable 2010 period. Gross margin as a percentage of revenue was 18.7% for the third quarter 2011 compared to 21.7% in the same period last year. Gross margin decreased due to the 8.2% decrease in revenue resulting in deteriorated overhead efficiencies as well as increased costs related to our efforts to improve customer satisfaction and on time delivery.

**Selling, General and Administrative Expenses.** For the three month period ended October 1, 2011, selling, general and administrative expenses were \$13.8 million compared with the three month period ended October 2, 2010 of \$12.2 million. The increase was primarily driven by increased employee compensation and benefits associated with the previously announced hiring of a new chief executive officer and transition related expenditures. We also experienced an increase in professional fees associated with the informal SEC inquiry of \$0.2 million, as well as the inclusion of \$0.3 million of expenses related to Olsen Medical since its date of acquisition.

**Facility Closure and Severance Costs.** Results of Operations include pre-tax charges of \$0.3 million and \$0.1 million for the three months ended October 1, 2011 and October 2, 2010, respectively, associated with employee severance costs. As of October 1, 2011, severance accruals totaled \$1.0 million and were included in other accrued expenses in the consolidated balance sheets.

**Other (Income) Expense.** Interest expense for the three month period ended October 1, 2011 decreased \$0.5 million, or 35.9%, to \$1.0 million from \$1.5 million for the comparable period in 2010. This decrease is attributable to the settlement of our interest rate swap agreement in November 2010 in connection with our debt refinancing activities. The derivative gain in the third quarter 2010 consists of a gain on interest rate swap valuation of \$0.4 million related to our interest rate swap that had not been designated as a hedge. We had no outstanding swap agreements during the third quarter 2011. Other expense for the three month period ended October 1, 2011 decreased \$0.9 million from the comparable period in 2010, from expense of \$0.7 million to income of \$0.2 million, due to favorable foreign currency exchange rate fluctuations on transactions denominated in foreign currencies.

**Provision for Income Taxes.** Our effective tax rate was 38.6% for the three month period ended October 1, 2011 as compared to 37.3% for the three month period ended October 2, 2010. Provision for income taxes decreased by \$1.8 million, or 84.4%, to \$0.3 million for the three month period ended October 1, 2011 from \$2.1 million for the comparable 2010 period primarily due to a \$4.8 million decrease in pre-tax income.

#### Nine Months Results of Operations

**Revenue.** Revenue for the nine month period ended October 1, 2011 increased \$9.7 million, or 3.7%, to \$274.5 million from \$264.9 million for the comparable 2010 period. Revenue for each of our principal product categories in these periods was as follows:

| Product Category | Nine Months Ended  |                    |
|------------------|--------------------|--------------------|
|                  | October 1,<br>2011 | October 2,<br>2010 |
|                  | (unaudited)        |                    |
| Instruments      | \$ 110.6           | \$ 103.1           |
| Implants         | 80.4               | 85.1               |
| Cases            | 65.6               | 60.1               |
| Other            | 17.9               | 16.6               |
| Total            | \$ 274.5           | \$ 264.9           |

The \$9.7 million, or 3.7%, increase in revenue resulted from increased demand within our instruments, cases, and other product lines, in addition to favorable foreign currency exchange rate fluctuations of \$4.2 million. These improvements were partially offset by lower demand in our implants product line. Overall, we experienced consistent revenues from our five largest OEM customers for the comparable periods in 2011 and 2010. Instrument revenue increased \$7.5 million. This increase was driven by increased revenue from other than our five largest OEM customers related to higher demand and timing of customer launches and also due to a \$2.1 million increase in our hospital direct distribution revenues. In addition, 2011 instrument revenue was increased by our recent Olsen Medical acquisition, which added \$0.7 million in revenue. These increases were partially offset by reduced demand from another customer which is not one of our five largest OEM customers. Implant revenue decreased \$4.6 million primarily due to a decrease in revenue from our five largest OEM customers as they experienced softer demand driven by lower than normal procedure growth rates. These decreases were partially offset by favorable foreign currency exchange rate fluctuations of \$1.7 million. Case revenue increased \$5.4 million. This increase is reflective of our focus to meet customer delivery requirements, as well as expanded diversification as revenue from our five largest OEM customers only represented \$0.1 million of the increase in revenue. Additionally, case revenues were impacted by favorable foreign currency exchange rate fluctuations of \$1.3 million. Other product revenue increased \$1.3 million primarily driven by favorable foreign currency exchange rate fluctuations of \$0.7 million.

**Gross Profit.** Gross profit for the nine month period ended October 1, 2011 increased \$0.1 million, or 0.1%, to \$57.3 million from \$57.2 million for the comparable 2010 period driven by the increase in revenue. Gross margin as a percentage of revenue was 20.9% for the nine month period ended October 1, 2011 compared to 21.6% in the same period last year. The deterioration in gross margin is due to the 3.7% increase in revenue being more than offset by a 10% increase in employee compensation driven primarily by increases in overtime incurred and headcount to meet customer delivery requirements and increased production levels.

**Selling, General and Administrative Expenses.** For the nine month period ended October 1, 2011, selling, general and administrative expenses were \$42.5 million compared with the nine month period ended October 2, 2010 of \$37.1 million. The increase was primarily driven by increased employee compensation and benefits associated with the previously announced hiring of a new chief executive officer and transition related expenditures as well as higher research and development costs. The increase was also driven by the inclusion of \$0.3 million of expenses related to Olsen Medical since its date of acquisition.

Facility Closure and Severance Costs. Results of Operations include pre-tax charges of \$2.5 million and \$0.9 million for the nine months ended October 1, 2011 and October 2, 2010, respectively, associated with employee cost reduction and efficiency actions, the closure of our Auburn, ME facility and employee severance costs. For the nine month period ended October 1, 2011, these costs are comprised of \$2.5 million of severance costs compared to \$0.6 million of severance costs in addition to \$0.3 million associated with moving costs for the period ended October 2, 2010. As of October 1, 2011, severance accruals related to these cost reduction and efficiency actions totaled \$1.0 million and were included in other accrued expenses in the consolidated balance sheets.

Other (Income) Expense. Interest expense for the nine month period ended October 1, 2011 decreased \$1.8 million, or 39.7%, to \$2.8 million from \$4.6 million for the comparable period in 2010. This decrease is attributable to the settlement of our interest rate swap agreement in November 2010 in connection with our debt refinancing activities, partially offset by an increase in borrowings. The derivative gain in the third quarter 2010 consists of a gain on interest rate swap valuation of \$1.2 million related to our interest rate swap that had not been designated as a hedge. We had no outstanding swap agreements during the third quarter 2011. Other expense for the nine month period ended October 1, 2011 decreased \$0.2 million from the comparable period in 2010, from \$0.8 million to \$0.6 million, due to comparable foreign currency exchange rate fluctuations on transactions denominated in foreign currencies

Provision for Income Taxes. Our effective tax rate was 32.4% for the nine month period ended October 1, 2011 as compared to 35.5% for the nine month period ended October 2, 2010. Provision for income taxes decreased by \$2.4 million, or 45.5%, to \$2.9 million for the nine month period ended October 1, 2011 from \$5.3 million for the comparable 2010 period primarily due to a \$6.0 million decrease in pre-tax income. Our effective tax rate in 2011 differed from the U.S. Federal statutory rate of 35% primarily due to the favorable impact of foreign income taxes as we benefited from an increase in income earned in foreign jurisdictions in 2011 where the statutory tax rate is lower than the Federal statutory rate.

## Liquidity and Capital Resources

### Liquidity

Our principal sources of liquidity in the nine month period ended October 1, 2011 were cash generated from operations and borrowings under our revolving credit agreements. Principal uses of cash in the nine month period ended October 1, 2011 included increased working capital and capital expenditures, funding the Olsen Medical acquisition as well as debt service. We expect that our principal uses of cash in the future will be to finance working capital, to pay for capital expenditures, to service debt and to fund possible future acquisitions.

We believe our cash resources will permit us to stay committed to our strategic plan of increasing our share in the orthopedic market, expanding into other medical device markets and expanding our hospital direct distribution business.

Operating Activities. Operating activities generated cash of \$18.2 million in the nine month period ended October 1, 2011 compared to \$11.9 million for the nine month period ended October 2, 2010, an increase of \$6.3 million. The increase in cash from operations is primarily due to a reduction in working capital requirements compared to prior year of \$10.1 million, partially offset by a decrease in net income of \$3.6 million and non-cash components of net income of \$0.2 million. Net cash used by working capital for the nine month period ended October 1, 2011 was \$4.3 million compared to \$14.4 million for the comparable prior year period.

Investing Activities. Capital expenditures of \$10.4 million were \$0.8 million higher in the nine month period ended October 1, 2011 than the \$9.6 million incurred during the nine month period ended October 2, 2010. The acquisition



of Olsen Medical used \$11.0 million of cash in the third quarter of 2011.

**Financing Activities.** Financing activities generated \$8.6 million of cash in the nine month period ended October 1, 2011 as compared to a \$3.0 million usage for the comparable prior year period due primarily to a decrease in net payments on bank term loans and capital lease obligations of \$12.2 million as well as an increase in cash provided from short term borrowings of \$3.5 million, partially offset by a reduction in net proceeds from our revolving credit agreement of \$4.2 million. The nine month period ended October 1, 2011, included \$7.5 million of net proceeds from our revolving credit agreement that reflects the incremental \$11.0 million of borrowings to fund the Olsen Medical acquisition.

#### Capital Expenditures

Capital expenditures totaled \$10.4 million for the nine months ended October 1, 2011, compared to \$9.6 million for the nine month period ended October 2, 2010. Expenditures were primarily for increased automation and replacement of existing equipment to more adequately meet customer demands. We expect to continue expansion and capability enhancement efforts in our Malaysia and other select facilities during 2011 to expand our manufacturing capabilities, product offerings and better meet customer needs.

#### Debt and Credit Facilities

As of October 1, 2011, we had an aggregate of approximately \$103.6 million of outstanding indebtedness, which consisted of an aggregate of \$94.5 million of borrowings under our revolving credit agreement; \$0.7 million of borrowings under our UK asset-based 24-month term note; \$5.9 million of borrowings under our Malaysia short-term credit facility; and \$2.5 million of capital lease obligations. We had three outstanding letters of credit as of October 1, 2011 in the amounts of \$5.0 million, \$2.0 million and \$0.2 million.

In March 2010, our Sheffield, UK unit obtained a £3.0 million facility, comprised of a 24-month asset-based term note and short-term revolver facility. The term note matures in March 2012 with monthly payments plus interest at 2.75% per year. The short-term revolver is due on demand and accrues interest at 3.50% per year. As of October 1, 2011, \$0.7 million was outstanding on the term loan and there were no borrowings on the short-term revolver. The term note and revolver are secured by certain assets of our Sheffield, UK unit, which had a net book value of approximately \$4.9 million as of October 1, 2011.

Our revolving credit agreement contains various financial covenants, including covenants requiring a maximum ratio of total debt to EBITDA and minimum fixed charges ratio of EBITDA and a \$30.0 million letter of credit sublimit. We were in compliance with these covenants under the senior credit facility as of October 1, 2011.

We believe that cash flow from operating activities and borrowings under our revolving credit agreement will be sufficient to fund currently anticipated working capital, planned capital spending and debt service requirements for the foreseeable future, including at least the next twelve months.

## Contractual Obligations and Commercial Commitments

The following table reflects our contractual obligations as of October 1, 2011.

|                                   | Total           | Payments Due By Period |                               |               |                      |
|-----------------------------------|-----------------|------------------------|-------------------------------|---------------|----------------------|
|                                   |                 | Less than<br>1 year    | 1-3 years<br>(In<br>Millions) | 4-5 years     | More than<br>5 years |
| Long-term debt obligations<br>(1) | \$ 95.2         | \$ 0.7                 | \$ 94.5                       | \$ -          | \$ -                 |
| Capital lease obligations         | 4.2             | 0.2                    | 2.6                           | 1.4           | -                    |
| Operating lease obligations       | 5.6             | 0.6                    | 3.9                           | 0.7           | 0.4                  |
| Purchase obligations (2)          | 28.6            | 3.4                    | 25.2                          | -             | -                    |
| <b>Total</b>                      | <b>\$ 133.6</b> | <b>\$ 4.9</b>          | <b>\$ 126.2</b>               | <b>\$ 2.1</b> | <b>\$ 0.4</b>        |

(1) Represents principal maturities only and, therefore, excludes the effects of interest. There are no scheduled payments for our revolving credit facility prior to maturity. Borrowings under the revolving credit facility bear interest at a variable rate based on the London Interbank Offer Rate (LIBOR) or a base rate determined by the lender's prime rate plus an applicable margin, as defined in the agreement. The applicable margin for borrowings under the revolving credit agreement ranges from 0.75% to 1.75% for base rate borrowings and 1.75% to 2.75% for LIBOR borrowings, subject to adjustment based on the average availability under the revolving line of credit facility.

(2) For the purposes of this table, contractual obligations for purchases of goods or services are defined as agreements that are enforceable and legally binding and that specify all significant terms, including: fixed or minimum quantities, fixed, minimum or variable price provisions; and the approximate timing of the transaction. Our purchase orders are normally based on our current manufacturing needs and are fulfilled by our vendors within a short time. We enter into blank orders with vendors that have preferred pricing terms; however, these orders are normally cancelable by us without penalty. Amounts predominantly represent purchase agreements to buy minimum quantities of cobalt chrome, titanium and nickel alloys through July 2014.

This table does not include liabilities for unrecognized tax benefits of \$6.3 million as reasonable estimates could not be made regarding the timing of future cash outflows associated with those liabilities.

## Off-Balance Sheet Arrangements

Our off-balance sheet arrangements include our operating leases and letters of credit, which are available under the revolving credit agreement. We had three letters of credit outstanding as of October 1, 2011 in the amounts of \$5.0 million, \$2.0 million and \$0.2 million.

## Environmental

Our facilities and operations are subject to extensive federal, state, local and foreign environmental and occupational health and safety laws and regulations. These laws and regulations govern, among other things, air emissions; wastewater discharges; the generation, storage, handling, use and transportation of hazardous materials; the handling and disposal of hazardous wastes; the cleanup of contamination; and the health and safety of our employees. Under

such laws and regulations, we are required to obtain permits from governmental authorities for some of our operations. If we violate or fail to comply with these laws, regulations or permits, we could be fined or otherwise sanctioned by regulators. We could also be held responsible for costs and damages arising from any contamination at our past or present facilities or at third-party waste disposal sites. We cannot completely eliminate the risk of contamination or injury resulting from hazardous materials, and we may incur material liability as a result of any contamination or injury.

We incurred minimal capital expenditures for environmental, health and safety in the nine month periods ended October 1, 2011 and October 2, 2010.

In connection with past acquisitions, we completed Phase I environmental assessments and did not identify any significant issues that we believe need to be remediated. We cannot be certain that environmental issues will not be discovered or arise in the future related to these acquisitions.

Based on information currently available, we do not believe that we have any material environmental liabilities.

#### Critical Accounting Policies and Estimates

The preparation of our consolidated financial statements in accordance with accounting principles generally accepted in the United States requires management to make estimates, judgments and assumptions that affect the reported amounts of assets, liabilities, revenues and expenses during the periods presented. Our Annual Report on Form 10-K for fiscal year ended January 1, 2011, includes a summary of the critical accounting policies we believe are the most important to aid in understanding our financial results. There have been no material changes to these critical accounting policies that impacted our reported amounts of assets, liabilities, revenues or expenses during the nine months ended October 1, 2011.

#### ITEM 3. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK

For financial market risks related to changes in interest rates, foreign currency exchange rates, commodity prices and the effects of inflation, reference is made to Item 7a "Quantitative and Qualitative Disclosures About Market Risk" contained in Part II of our Annual Report on Form 10-K for the fiscal year ended January 1, 2011. Our exposure to these risks, at the end of the third quarter covered by this report, has not changed materially since January 1, 2011.

#### ITEM 4. CONTROLS AND PROCEDURES

This Report includes the certifications of our Chief Executive Officer and Chief Financial Officer required by Rule 13a-14 of the Securities Exchange Act of 1934 (the "Exchange Act"). See Exhibits 31.1 and 31.2. This Item 4 includes information concerning the controls and control evaluations referred to in those certifications.

(a) Evaluation of Disclosure Controls and Procedures

Disclosure controls and procedures (as defined in Rules 13a-15(e) and 15d-15(e) under the Exchange Act) are designed to ensure that information required to be disclosed in reports filed or submitted under the Exchange Act is recorded, processed, summarized, and reported within the time periods specified in the SEC rules and forms and that such information is accumulated and communicated to management, including the Chief Executive Officer and the Chief Financial Officer, to allow timely decisions regarding required disclosures.

In connection with the preparation of this Report, our management, under the supervision and with the participation of the Chief Executive Officer and Chief Financial Officer, conducted an evaluation of the effectiveness of the design and operation of our disclosure controls and procedures as of the end of the fiscal quarter covered by this report on Form 10-Q. Based on that evaluation, our Chief Executive Officer and Chief Financial Officer have concluded that our disclosure controls and procedures were effective as of October 1, 2011.

(b) Changes in Internal Control over Financial Reporting

There have been no changes in our “internal control over financial reporting” (as defined in Rule 13a-15(f) of the Exchange Act) that occurred during the fiscal quarter covered by this report on Form 10-Q that has materially affected, or is reasonably likely to materially affect, our internal control over financial reporting.

(c) Other Matters

The Corporation is in the process of integrating its multiple facilities into its existing Enterprise Resource Planning (ERP) platform. An ERP system is a fully-integrated set of programs and databases that incorporate order processing, production planning and scheduling, purchasing, accounts receivable and inventory management and accounting. In connection with this ERP consolidation, the Corporation will update its internal controls over financial reporting, as necessary, to accommodate modifications to its business processes and accounting procedures. The Corporation does not believe that this ERP system consolidation will have an adverse effect on the Corporation’s internal control over financial reporting.

## PART II OTHER INFORMATION

### ITEM 1. LEGAL PROCEEDINGS

#### SEC Inquiry

Following the discovery of the accounting irregularities at our Sheffield, UK operating unit, the Audit Committee self-reported the matter to the staff of the SEC in October 2007. Thereafter, the SEC commenced an informal inquiry regarding this matter.

We have fully cooperated with the SEC in its investigation. At this time we are unable to predict the time period necessary to resolve the investigation or the ultimate resolution thereof. To date, considerable legal, tax and accounting expenses have been incurred in connection with our Audit Committee’s investigation into this matter and expenditures may continue to be incurred in the future with regard to the SEC’s investigation. It is also possible that the investigation may continue to require management’s time and attention and accounting and legal resources, which could otherwise be devoted to the operation of our business. Moreover, any action by the SEC against us, or members of our management, may cause us to be subject to injunctions, fines or other penalties or sanctions or result in private civil actions, loss of key personnel or other adverse consequences and may require us to devote additional time and resources to these matters. The investigation may adversely affect our ability to obtain, and /or increase the cost of

## Edgar Filing: Symmetry Medical Inc. - Form 10-Q

obtaining, directors' and officers' liability insurance and/or other types of insurance, which could have a material adverse affect on our business, results of operations and financial condition. In addition, the SEC investigation and the remedies applied may affect certain of our business relationships and consequently may have an adverse affect on our business in the future.

### ITEM 1A. RISK FACTORS

In addition to the other information set forth in this report, you should carefully consider the factors discussed in Part I, Item 1A "Risk Factors" contained in our Annual Report on Form 10-K for the fiscal year ended January 1, 2011, which could materially affect our business, financial condition or future results. There have been no material changes from the risk factors disclosed in our Annual Report on Form 10-K

### ITEM 5. OTHER INFORMATION

On November 3, 2011 Mr. Hite was paid a cash bonus of 9% of his salary (\$31,500) for his leadership of the successful implementation of version 9 of the Company's Epicor Enterprise Resource Planning system software in the Company's Instrument Division (the "Project"). There were approximately 15 people involved on the Project team, and all team members received a cash bonus as a percent of their respective salary. The amount of their bonus depended on the extent to which they were involved in the project and the extent to which their work resulted in the Project's success. The Board of Directors and Compensation Committee reviewed Mr. Hite's involvement in the Project, his contributions to its success and the relative amounts paid to others who had similar levels of involvement. It is determined that a cash bonus of 9% was appropriate in light of all applicable circumstances.

### ITEM 6. EXHIBITS

31.1 Certification of Chief Executive Officer required by Item 307 of Regulation S-K as promulgated by the Securities and Exchange Commission and pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.\*

31.2 Certification of Chief Financial Officer required by Item 307 of Regulation S-K as promulgated by the Securities and Exchange Commission and pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.\*

32.1 Certification of Chief Executive Officer and Chief Financial Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.\*

|         |   |
|---------|---|
| 101.INS | XBRL Instance Document~                                 |
| 101.SCH | XBRL Taxonomy Extension Schema Document~                |
| 101.CAL | XBRL Taxonomy Extension Calculation Linkbase Document~  |
| 101.DEF | XBRL Taxonomy Extension Definition Linkbase Document~   |
| 101.LAB | XBRL Taxonomy Extension Label Linkbase Document~        |
| 101.PRE | XBRL Taxonomy Extension Presentation Linkbase Document~ |

\* Filed concurrently herewith.

~ In accordance with Rule 406T under Regulation S-T, the XBRL-related information in Exhibit 101 shall be deemed "furnished" and not "filed."



SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

SYMMETRY MEDICAL INC.

By /s/ Thomas J. Sullivan  
Thomas J. Sullivan,  
President and Chief Executive Officer  
(Principal Executive Officer)

By /s/ Fred L. Hite  
Fred L. Hite,  
Senior Vice President and Chief Financial  
Officer  
(Principal Financial Officer)

November 8, 2011